The EU apparently expects the vaccine manufacturer Johnson & Johnson to apply for approval for its Covid vaccine in February. This is what EU Health Commissioner Stella Kyriakides said on Wednesday in a meeting with the conservative EPP group in the EU Parliament, said CDU MP Peter Liese.
Johnson & Johnson has developed what is known as a vector vaccine. This contains an adenovirus that is harmless to humans and is unable to multiply. The genetic information for the Sars-CoV-2 spike protein was built into this virus. The technique has already been used for a vaccine against Ebola.
The EU has 200 million doses of the vaccine plus an option for an additional 200 million doses secured. Johnson & Johnson is testing the vaccine in two large phase III studies – both with a single dose and with two doses of vaccine. middle of December announced the groupthat he expects data from the first Phase III study in late January.
“If that works, then we have the fourth corona vaccine. The Johnson & Johnson vaccine has the advantage that with this vaccine you only need one shot to be adequately protected and it is much easier to process, store and transport than the Biontech / Pfizer vaccine, ” announced Liese.
Corona vaccines are already approved by Biontech/Pfizer such as Modern. AstraZeneca also has on January 12th applied for approval of his product in the EU. The European Medicines Agency EMA announced that a decision could probably be made as early as the end of January.